Amylyx Pharmaceuticals

AMLX

Market cap $1.57B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S (“Gubra”), a company specializing in peptide-based drug discovery and preclinical contract research services. “We are very.

Austin-based Saturn V Capital Management added 1.3 million shares of Amylyx Pharmaceuticals in the third quarter. The overall position increased in value by $41.2 million from quarter to quarter.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial.

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

New York City-based Commodore Capital bought nearly 4.1 million shares, increasing portfolio value by an estimated $55 million. The position represents 2.7% of 13F reportable assets under management (AUM).

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Nov. 28, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.

California-based TCG Crossover bought 300,000 shares of Amylyx Pharmaceuticals for an estimated $46.8 million in the third quarter. At quarter-end, TCG Crossover reported holding 6.2 million total shares of Amylyx shares valued at $84.9 million.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). If you currently own shares of Amylyx Pharmaceuticals stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=22470 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenleg.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). If you currently own shares of Amylyx Pharmaceuticals stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=22470 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenleg.

Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lindsey Allen Justin Klee - Co-Founder, Co-CEO & Director Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Founder, Co-CEO & Director Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research Division Joseph Thome - TD Cowen, Research Division Kevin Strang - Goldman Sachs Group, Inc., Research Division Marc Goodman - Leerink Partners LLC, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Christopher Chen - Robert W. Baird & Co. Incorporated, Research Division Susan Chor Ananda Ghosh - H.C.